Spyros is an experienced biopharmaceutical executive, recognized neuroscientist, neurodegenerative disease clinician and change agent. Prior to joining Vigil. he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and Head of Research & Development and Chief Medical Officer at Cavion. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Spyros has overseen a broad spectrum of biopharmaceutical development programs (small molecules, biologics, gene therapy) leading to successful regulatory filings and new product launches worldwide. He holds appointments as Consultant with Massachusetts General Hospital and Voluntary Professor of Neurology with the University of Miami, Miller School of Medicine. He was involved in groundbreaking research that led to the characterization of genetic forms of Parkinson’s disease and development of methodologies that revolutionized the quantification of neuromotor function in clinical research settings. Spyros received his MD and PhD from University of Patras, School of Health Sciences, Faculty of Medicine (Greece).